EGFR and non-small cell lung carcinoma: In summary, NSCLC patients with higher serum TrxR1 activity had poorer prognosis, suggesting that serum TrxR1 may be a useful clinical biomarkers in prognostic evaluation in EGFR wild type, ALK negative advanced NSCLC.